<DOC>
	<DOCNO>NCT00071812</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy 3 different dos belimumab , administer addition standard therapy , patient rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>A Safety Efficacy Study LymphoStat-B™ ( Monoclonal Anti-BLyS Antibody ) Subjects With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description>The purpose study evaluate safety efficacy three different dos belimumab ( 1 mg/kg , 4 mg/kg , 10 mg/kg ) , administer addition standard therapy , compare placebo plus standard therapy patient RA . All patient dose Days 0 , 14 , 28 , every 28 day remainder 24 week . Patients complete 24-week period could enter 24-week open-label extension ; belimumab patient receive dose switch 10 mg/kg investigator 's discretion former placebo patient receive belimumab 10 mg/kg .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Primary Diagnosis RA least 1 year Failed least 1 disease modify antirheumatic drug ( DMARD ) due toxicity lack efficacy . These drug must include 1 follow : methotrexate , parenteral gold , sulfasalazine , leflunomide , tumor necrosis factoralpha ( TNFα ) inhibitor ( infliximab , etanercept adalimumab ) Active RA disease least moderate disease activity Be stable RA treatment regimen least past 60 day ( DMARDS ) ; nonsteroidal antiinflammatory drug ( NSAIDs ) steroid must stable dose last 30 day Primary Received nonFDA approve investigational agent within last 28 day Currently receive receive within last 60 day follow : TNFαinhibitors ( infliximab , etanercept , adalimumab ) interleukin1 receptor antagonist ( anakinra ) Currently receive receive within last 6 month follow : antiCD20 antibody ( rituximab ) cyclophosphamide Steroid injection joint within last 30 day History hypogammaglobulinemia immunoglobulin A ( IgA ) deficiency History chronic infection active within last 6 month , herpes zoster within last 90 day , infection require hospitalization intravenous medication within last 60 day Human immunodeficiency virus ( HIV ) , HepatitisB , HepatitisC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>RA</keyword>
</DOC>